Video Series

The Center for Medicare and Medicaid Innovation (CMMI) was a strong collaborator during the Oncology Care Mode (OCM), but the timing of the Enhancing Oncology Model came as a surprise.

Dr Cleary outlines strategies to individualize care for patients diagnosed with upper GI and esophageal cancer.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, provide insights regarding gastroesophageal treatment decisions when FDA labels don’t reflect clinical practice guidelines.

Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Expert panelists explore prevalence and disparities of MDD across patient populations.

Jorge Larranaga, MD, provides his opinion regarding the criticality of urgency in LN treatment.

Jorge Larranaga, MD, and Alvin Wells, MD, PhD, describe the progression of SLE to lupus nephritis.

Immune checkpoint inhibitors can play a key role in the treatment of upper-GI and esophageal cancer.

Key opinion leaders navigate unmet needs across the treatment landscape of gastroesophageal cancer.

Drs Cannon and Rothrock provide insights into their process for defining value among newly launched MDD treatments.

Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Alvin Wells, MD, PhD, opens a discussion surrounding systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Key opinion leaders provide their final thoughts on treatment management for patients with MDS.

The expert panel looks to future treatment management for patients with myelodysplastic syndrome.

Laura Bobolts, PharmD, BCOP, discusses key cost drivers impacting treatments for upper GI and esophageal cancers.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, PhD, explore the evolution of treatment for patients with upper GI and esophageal cancer, including first- and second-line treatment strategies for gastroesophageal cancer.

Panelists provide their key considerations when determining appropriate treatment options for patients with major depressive disorder.

Key opinion leaders discuss the importance of early effective treatment for patients with MDD.

Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.

Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.

Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.

Major depressive disorder treatment failure can lead to subsequent costs and poor outcomes, affecting payer considerations in the treatment landscape.

Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

The SOGUG-AUREA study explored overall survival of atezolizumab plus split-dose cisplatin-gemcitabine in patients with locally advanced and metastatic urothelial cancer.

Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer.